Pixantrone regulatory update

Cell Therapeutics said FDA will conduct a standard review of an NDA for pixantrone to treat relapsed or refractory aggressive non-Hodgkin's lymphoma (NHL). The PDUFA date is April 23, 2010. Cell Thera...